O	0	6	Effect
O	7	9	of
B-intervention	10	21	Acupuncture
O	22	24	vs
B-intervention	25	29	Sham
I-intervention	30	41	Acupuncture
O	42	44	or
B-control	45	53	Waitlist
I-control	54	61	Control
O	62	64	on
B-condition	65	70	Joint
I-condition	71	75	Pain
O	76	83	Related
O	84	86	to
O	87	96	Aromatase
O	97	107	Inhibitors
O	108	113	Among
O	114	119	Women
O	120	124	With
O	125	130	Early
O	130	131	-
O	131	136	Stage
O	137	143	Breast
O	144	150	Cancer
O	150	151	:
O	152	153	A
O	154	164	Randomized
O	165	173	Clinical
O	174	179	Trial
O	179	180	.

O	181	196	Musculoskeletal
O	197	205	symptoms
O	206	209	are
O	210	213	the
O	214	218	most
O	219	225	common
O	226	233	adverse
O	234	241	effects
O	242	244	of
O	245	254	aromatase
O	255	265	inhibitors
O	266	269	and
O	270	275	often
O	276	282	result
O	283	285	in
O	286	293	therapy
O	294	309	discontinuation
O	309	310	.

O	311	316	Small
O	317	324	studies
O	325	332	suggest
O	333	337	that
O	338	349	acupuncture
O	350	353	may
O	354	362	decrease
O	363	372	aromatase
O	373	382	inhibitor
O	382	383	-
O	383	390	related
O	391	396	joint
O	397	405	symptoms
O	405	406	.

O	407	409	To
O	410	419	determine
O	420	423	the
O	424	430	effect
O	431	433	of
O	434	445	acupuncture
O	446	448	in
O	449	457	reducing
O	458	467	aromatase
O	468	477	inhibitor
O	477	478	-
O	478	485	related
O	486	491	joint
O	492	496	pain
O	496	497	.

O	498	508	Randomized
O	509	517	clinical
O	518	523	trial
O	524	533	conducted
O	534	536	at
O	537	539	11
O	540	548	academic
O	549	556	centers
O	557	560	and
O	561	569	clinical
O	570	575	sites
O	576	578	in
O	579	582	the
B-location	583	589	United
I-location	590	596	States
O	597	601	from
O	602	607	March
O	608	612	2012
O	613	615	to
O	616	624	February
O	625	629	2017
O	630	631	(
O	631	636	final
O	637	641	date
O	642	644	of
O	645	651	follow
O	651	652	-
O	652	654	up
O	654	655	,
O	656	665	September
O	666	667	5
O	667	668	,
O	669	673	2017
O	673	674	)
O	674	675	.

O	676	684	Eligible
O	685	693	patients
O	694	698	were
B-eligibility	699	713	postmenopausal
I-eligibility	714	719	women
I-eligibility	720	724	with
I-eligibility	725	730	early
I-eligibility	730	731	-
I-eligibility	731	736	stage
I-eligibility	737	743	breast
I-eligibility	744	750	cancer
I-eligibility	751	754	who
I-eligibility	755	759	were
I-eligibility	760	766	taking
I-eligibility	767	769	an
I-eligibility	770	779	aromatase
I-eligibility	780	789	inhibitor
I-eligibility	790	793	and
I-eligibility	794	800	scored
I-eligibility	801	803	at
I-eligibility	804	809	least
I-eligibility	810	811	3
I-eligibility	812	814	on
I-eligibility	815	818	the
I-eligibility	819	824	Brief
I-eligibility	825	829	Pain
I-eligibility	830	839	Inventory
I-eligibility	840	845	Worst
I-eligibility	846	850	Pain
I-eligibility	851	852	(
I-eligibility	852	855	BPI
I-eligibility	855	856	-
I-eligibility	856	858	WP
I-eligibility	858	859	)
I-eligibility	860	864	item
I-eligibility	865	866	(
I-eligibility	866	871	score
I-eligibility	872	877	range
I-eligibility	877	878	,
I-eligibility	879	880	0
I-eligibility	880	881	-
I-eligibility	881	883	10
I-eligibility	883	884	;
I-eligibility	885	891	higher
I-eligibility	892	898	scores
I-eligibility	899	907	indicate
I-eligibility	908	915	greater
I-eligibility	916	920	pain
I-eligibility	920	921	)
O	921	922	.

O	923	931	Patients
O	932	936	were
O	937	947	randomized
O	948	949	2
O	949	950	:
O	950	951	1
O	951	952	:
O	952	953	1
O	954	956	to
O	957	960	the
O	961	965	true
O	966	977	acupuncture
O	978	979	(
O	979	980	n
O	981	982	=
B-intervention-participants	983	986	110
O	986	987	)
O	987	988	,
O	989	993	sham
O	994	1005	acupuncture
O	1006	1007	(
O	1007	1008	n
O	1009	1010	=
B-control-participants	1011	1013	59
O	1013	1014	)
O	1014	1015	,
O	1016	1018	or
O	1019	1027	waitlist
O	1028	1035	control
O	1036	1037	(
O	1037	1038	n
O	1039	1040	=
B-control-participants	1041	1043	57
O	1043	1044	)
O	1045	1050	group
O	1050	1051	.

O	1052	1056	True
O	1057	1068	acupuncture
O	1069	1072	and
O	1073	1077	sham
O	1078	1089	acupuncture
O	1090	1099	protocols
O	1100	1109	consisted
O	1110	1112	of
O	1113	1115	12
O	1116	1127	acupuncture
O	1128	1136	sessions
O	1137	1141	over
O	1142	1143	6
O	1144	1149	weeks
O	1150	1151	(
O	1151	1152	2
O	1153	1161	sessions
O	1162	1165	per
O	1166	1170	week
O	1170	1171	)
O	1171	1172	,
O	1173	1181	followed
O	1182	1184	by
O	1185	1186	1
O	1187	1194	session
O	1195	1198	per
O	1199	1203	week
O	1204	1207	for
O	1208	1209	6
O	1210	1215	weeks
O	1215	1216	.

O	1217	1220	The
O	1221	1229	waitlist
O	1230	1237	control
O	1238	1243	group
O	1244	1247	did
O	1248	1251	not
O	1252	1259	receive
O	1260	1263	any
O	1264	1276	intervention
O	1276	1277	.

O	1278	1281	All
O	1282	1294	participants
O	1295	1299	were
O	1300	1307	offered
O	1308	1310	10
O	1311	1322	acupuncture
O	1323	1331	sessions
O	1332	1334	to
O	1335	1337	be
O	1338	1342	used
O	1343	1350	between
O	1351	1356	weeks
O	1357	1359	24
O	1360	1363	and
O	1364	1366	52
O	1366	1367	.

O	1368	1371	The
O	1372	1379	primary
O	1380	1383	end
O	1384	1389	point
O	1390	1393	was
O	1394	1397	the
B-outcome-Measure	1398	1399	6
I-outcome-Measure	1399	1400	-
I-outcome-Measure	1400	1404	week
I-outcome-Measure	1405	1408	BPI
I-outcome-Measure	1408	1409	-
I-outcome-Measure	1409	1411	WP
I-outcome-Measure	1412	1417	score
O	1417	1418	.

O	1419	1423	Mean
O	1424	1425	6
O	1425	1426	-
O	1426	1430	week
O	1431	1434	BPI
O	1434	1435	-
O	1435	1437	WP
O	1438	1444	scores
O	1445	1449	were
O	1450	1458	compared
O	1459	1461	by
O	1462	1467	study
O	1468	1473	group
O	1474	1479	using
O	1480	1486	linear
O	1487	1497	regression
O	1497	1498	,
O	1499	1507	adjusted
O	1508	1511	for
O	1512	1520	baseline
O	1521	1525	pain
O	1526	1529	and
O	1530	1544	stratification
O	1545	1552	factors
O	1553	1554	(
O	1554	1564	clinically
O	1565	1575	meaningful
O	1576	1586	difference
O	1587	1596	specified
O	1597	1599	as
O	1600	1601	2
O	1602	1608	points
O	1608	1609	)
O	1609	1610	.

O	1611	1616	Among
B-total-participants	1617	1620	226
O	1621	1631	randomized
O	1632	1640	patients
O	1641	1642	(
O	1642	1646	mean
O	1647	1648	[
O	1648	1650	SD
O	1650	1651	]
O	1652	1655	age
O	1655	1656	,
B-age	1657	1659	60
I-age	1659	1660	.
I-age	1660	1661	7
I-age	1662	1663	[
I-age	1663	1664	8
I-age	1664	1665	.
I-age	1665	1666	6
I-age	1666	1667	]
I-age	1668	1673	years
O	1673	1674	;
O	1675	1677	88
O	1677	1678	%
B-ethinicity	1679	1684	white
O	1684	1685	;
O	1686	1690	mean
O	1691	1692	[
O	1692	1694	SD
O	1694	1695	]
O	1696	1704	baseline
O	1705	1708	BPI
O	1708	1709	-
O	1709	1711	WP
O	1712	1717	score
O	1717	1718	,
O	1719	1720	6
O	1720	1721	.
O	1721	1722	6
O	1723	1724	[
O	1724	1725	1
O	1725	1726	.
O	1726	1727	5
O	1727	1728	]
O	1728	1729	)
O	1729	1730	,
B-total-participants	1731	1734	206
O	1735	1736	(
O	1736	1738	91
O	1738	1739	.
O	1739	1740	1
O	1740	1741	%
O	1741	1742	)
O	1743	1752	completed
O	1753	1756	the
O	1757	1762	trial
O	1762	1763	.

O	1764	1768	From
O	1769	1777	baseline
O	1778	1780	to
O	1781	1782	6
O	1783	1788	weeks
O	1788	1789	,
O	1790	1793	the
B-outcome	1794	1798	mean
I-outcome	1799	1807	observed
I-outcome	1808	1811	BPI
I-outcome	1811	1812	-
I-outcome	1812	1814	WP
I-outcome	1815	1820	score
O	1821	1830	decreased
O	1831	1833	by
B-iv-cont-mean	1834	1835	2
I-iv-cont-mean	1835	1836	.
I-iv-cont-mean	1836	1838	05
I-iv-cont-mean	1839	1845	points
O	1846	1847	(
O	1847	1854	reduced
O	1855	1859	pain
O	1859	1860	)
O	1861	1863	in
O	1864	1867	the
O	1868	1872	true
O	1873	1884	acupuncture
O	1885	1890	group
O	1890	1891	,
O	1892	1894	by
B-iv-cont-mean	1895	1896	1
I-iv-cont-mean	1896	1897	.
I-iv-cont-mean	1897	1899	07
I-iv-cont-mean	1900	1906	points
O	1907	1909	in
O	1910	1913	the
O	1914	1918	sham
O	1919	1930	acupuncture
O	1931	1936	group
O	1936	1937	,
O	1938	1941	and
O	1942	1944	by
B-cv-cont-mean	1945	1946	0
I-cv-cont-mean	1946	1947	.
I-cv-cont-mean	1947	1949	99
I-cv-cont-mean	1950	1956	points
O	1957	1959	in
O	1960	1963	the
O	1964	1972	waitlist
O	1973	1980	control
O	1981	1986	group
O	1986	1987	.

O	1988	1991	The
B-outcome	1992	2000	adjusted
I-outcome	2001	2011	difference
O	2012	2015	for
B-outcome	2016	2020	true
I-outcome	2021	2032	acupuncture
I-outcome	2033	2035	vs
I-outcome	2036	2040	sham
I-outcome	2041	2052	acupuncture
O	2053	2056	was
B-iv-cont-mean	2057	2058	0
I-iv-cont-mean	2058	2059	.
I-iv-cont-mean	2059	2061	92
I-iv-cont-mean	2062	2068	points
O	2069	2070	(
O	2070	2072	95
O	2072	2073	%
O	2074	2076	CI
O	2076	2077	,
O	2078	2079	0
O	2079	2080	.
O	2080	2082	20
O	2082	2083	-
O	2083	2084	1
O	2084	2085	.
O	2085	2087	65
O	2087	2088	;
O	2089	2090	P
O	2091	2092	=
O	2093	2094	.
O	2094	2096	01
O	2096	2097	)
O	2098	2101	and
O	2102	2105	for
B-outcome	2106	2110	true
I-outcome	2111	2122	acupuncture
I-outcome	2123	2125	vs
I-outcome	2126	2134	waitlist
I-outcome	2135	2142	control
O	2143	2146	was
B-cv-cont-mean	2147	2148	0
I-cv-cont-mean	2148	2149	.
I-cv-cont-mean	2149	2151	96
I-cv-cont-mean	2152	2158	points
O	2159	2160	(
O	2160	2162	95
O	2162	2163	%
O	2164	2166	CI
O	2166	2167	,
O	2168	2169	0
O	2169	2170	.
O	2170	2172	24
O	2172	2173	-
O	2173	2174	1
O	2174	2175	.
O	2175	2177	67
O	2177	2178	;
O	2179	2180	P
O	2181	2182	=
O	2183	2184	.
O	2184	2186	01
O	2186	2187	)
O	2187	2188	.

O	2189	2197	Patients
O	2198	2200	in
O	2201	2204	the
O	2205	2209	true
O	2210	2221	acupuncture
O	2222	2227	group
O	2228	2239	experienced
O	2240	2244	more
B-outcome	2245	2250	grade
I-outcome	2251	2252	1
I-outcome	2253	2261	bruising
O	2262	2270	compared
O	2271	2275	with
O	2276	2284	patients
O	2285	2287	in
O	2288	2291	the
O	2292	2296	sham
O	2297	2308	acupuncture
O	2309	2314	group
O	2315	2316	(
B-iv-bin-percent	2316	2318	47
I-iv-bin-percent	2318	2319	%
O	2320	2322	vs
B-cv-bin-percent	2323	2325	25
I-cv-bin-percent	2325	2326	%
O	2326	2327	;
O	2328	2329	P
O	2330	2331	=
O	2332	2333	.
O	2333	2335	01
O	2335	2336	)
O	2336	2337	.

O	2338	2343	Among
O	2344	2358	postmenopausal
O	2359	2364	women
O	2365	2369	with
O	2370	2375	early
O	2375	2376	-
O	2376	2381	stage
O	2382	2388	breast
O	2389	2395	cancer
O	2396	2399	and
O	2400	2409	aromatase
O	2410	2419	inhibitor
O	2419	2420	-
O	2420	2427	related
O	2428	2439	arthralgias
O	2439	2440	,
O	2441	2445	true
O	2446	2457	acupuncture
O	2458	2466	compared
O	2467	2471	with
O	2472	2476	sham
O	2477	2488	acupuncture
O	2489	2491	or
O	2492	2496	with
O	2497	2505	waitlist
O	2506	2513	control
O	2514	2522	resulted
O	2523	2525	in
O	2526	2527	a
O	2528	2541	statistically
O	2542	2553	significant
O	2554	2563	reduction
O	2564	2566	in
O	2567	2572	joint
O	2573	2577	pain
O	2578	2580	at
O	2581	2582	6
O	2583	2588	weeks
O	2588	2589	,
O	2590	2598	although
O	2599	2602	the
O	2603	2611	observed
O	2612	2623	improvement
O	2624	2627	was
O	2628	2630	of
O	2631	2640	uncertain
O	2641	2649	clinical
O	2650	2660	importance
O	2660	2661	.

O	2662	2676	ClinicalTrials
O	2676	2677	.
O	2677	2680	gov
O	2681	2691	Identifier
O	2691	2692	:
O	2693	2704	NCT01535066
O	2704	2705	.
